TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03497208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: The technique is about applying a dermaroller equipped with 0.25 mm needles over the vitiligo area.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cell suspension
Description: The technique involves preparation of a cell suspension (keratinocyte/melanocyte) prepared by trypsinization from a non-lesioned part of a patient's scalp skin and transepidermal delivery using a dermarollerequipped with 0.25 mm needles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cell suspension
Description: The technique involves preparation of a cell suspension (keratinocyte/melanocyte) prepared by trypsinization from a non-lesioned part of a patient's scalp skin and transepidermal delivery using a dermarollerequipped with 0.25 mm needles.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: The patient will receive phototherapy UVB-NB in the lesions of vitiligo after 15 days of the surgical procedure.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: The patient will receive phototherapy UVB-NB in the lesions of vitiligo after 15 days of the surgical procedure.
Study: NCT01530061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg Breakfast
Description: Egg, Toast and Jelly
Study: NCT01394211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO
Study: NCT01530061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg Breakfast
Description: Egg, Toast and Jelly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bagel Breakfast
Description: Bagel, Cream Cheese and Yogurt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bagel Breakfast
Description: Bagel, Cream Cheese and Yogurt
Study: NCT04007081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: collection of approximately 40 mL of bone marrow aspirate
Study: NCT01394211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given PO
Study: NCT04007081

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging of Salivary Glands
Description: Salivary gland size will be measured by ultrasound.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salivary Assay
Description: Whole saliva production rates (sialometry) will be measured under unstimulated (first passive drool method) and stimulated (chewing gum) saliva collection conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Instruments
Description: Participants will self-assess with the following Quality of Life (QoL) surveys: University of Michigan Xerostomia related quality of life scale (XeQOL), the MD Anderson Dysphagia Index (MDADI), and the VAS xerostomia questionnaire.
Study: NCT00123396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BioCASES and BioTESTS
Study: NCT02220205

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PelvicSim

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Manufacturer model
Study: NCT01979445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 600 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 600 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 600 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel 60 mg single oral dose
Study: NCT00280631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezatiostat Hydrochlorine
Description: Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.
Study: NCT03982368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 20 μg/ml
Description: one drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 20 μg/ml + vehicle
Description: one drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (every 6-8 hours).~rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: one drop of vehicle will be instilled in both eyes three times daily (every 6-8 hours)
Study: NCT01465997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: 50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine-Controlled Release (CBZ-CR)
Description: 200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum 3.5 Years)
Study: NCT03767816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Rectus sheath block
Description: Ultrasound guided rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml around umbilicus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Rectus sheath block
Description: Ultrasound guided rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml around umbilicus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound erector spinae plane block
Description: Ultrasound guided erector spinae plane block with 0.2% ropivacaine (Fresenius Kabi) 40ml at T7 level
Study: NCT04040114

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Molemap Skin Cancer Triage Artificial Intelligence Device
Description: This device/software incorporates artificial intelligence to provide a diagnostic aide for clinicians of patients with potentially malignant skin lesions. The software is supported by the use of cameras for acquisition of images.
Study: NCT04029948

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser En Bloc Resection Of bladder Tumor
Description: Using laser beam starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electro-surgical En Bloc Resection Of bladder Tumor
Description: Using electro-surgical loop starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
Study: NCT02335866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: test groups
Description: At the test sites, the previously prepared PRF was positioned over the recession defects, the coronal margin of the PRF was placed at the CEJ

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control groups
Description: Split-full-split thickness flap incisions were performed in a coronal-apical direction. The papillae adjacent to the involved tooth were de-epithelialized to create a connective tissue bed. The gingival flap was repositioned without tension, with its margin located on the enamel, on the test and control sides. It was held in that position with 5-0 resoble sutures
Study: NCT01520012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 100 mg
Description: Period1: YH4808 100 mg bid fasting condition for 7days Period2: YH4808 100 mg bid fed condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 100 mg
Description: Period1: YH4808 100 mg bid fed condition for 7days Period2: YH4808 100 mg bid fasting condition for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 300 mg
Description: Period1: YH4808 300 mg fasting condition Period2: YH4808 300 mg fed condition(standard meal) Period3: YH4808 300 mg fed condition(high fat meal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 300 mg
Description: Period1: YH4808 300 mg fed condition(high fat meal) Period2: YH4808 300 mg fasting condition Period3: YH4808 300 mg fed condition(standard meal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 300 mg
Description: Period1: YH4808 300 mg fed condition(standard meal) Period2: YH4808 300 mg fed condition(high fat meal) Period3: YH4808 300 mg fasting condition
Study: NCT01115101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Oxycodon
Description: Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piritramid
Description: Patients assigned to the PCA group received a single use intravenous PCA device (Vygon, Medical Products, Aachen, Germany) with a 30ml deposit of 9% sodium chloride solution containing 60mg piritramide. Bolus injection of 0.5ml was administered by the patient herself if needed, with a lock out interval of 5 minutes~Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean. The PCA was discontinued after 24 hours or earlier if demanded.
Study: NCT02660502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biochaperone insulin lispro 0.1 U/kg
Description: Injection of a single dose of BioChaperone insulin lispro at the dose of 0.1 U/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biochaperone insulin lispro 0.2 U/kg
Description: Injection of a single dose of BioChaperone insulin lispro at the dose of 0.2 U/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biochaperone insulin lispro 0.4 U/kg
Description: Injection of a single dose of BioChaperone insulin lispro at the dose of 0.4 U/kg
Study: NCT01394211

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo definitive surgery
Study: NCT02052323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate/mefloquine (AS/MQ)
Description: * artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours~* mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours~* primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours
Study: NCT02660502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Injection of a single dose of Humalog® at the dose of 0.2 U/kg
Study: NCT00660309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Irbesartan 300 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril
Description: Captopril 25 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril
Description: Captopril 25 mg tablet
Study: NCT03274128

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radon therapeutic baths and inhalations
Description: The natural water with low mineralized content plays a major therapeutic role with the parameters of Rn 303,1-441,5 Bq/l. In the treatment rooms (inhalation, cabins with baths and swimming pool) measurement of alpha radiation was 184,4-450,0 MeV. The measurements were analyzed every 3 months at the Institute of Occupational Medicine in the Department of Radiation Protection in Lodz, Poland. Among the types of treatments used in the therapy there was: comprehensive radon bath - with the temperature of 37 °C, duration 15 min., the treatments were performed every 2nd day, whereas radon inhalations lasted 15 min. with the temp. 37 °C- treatments were performed every 2nd day from Monday to Friday. Baths and inhalations were performed interchangeably and the total number of radon treatments during one stay was 15.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotherapy
Description: It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min,
Study: NCT03839901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: Home exercise programme with participants followed up at week 1, 4, 6 and 8.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: Home exercise programme with participants followed up at week 1, 4, 6 and 8.
Study: NCT00809055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine citrate
Description: Caffeine to be administered as outlined to compare efficacy of different dosages.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate
Description: Caffeine to be administered as outlined to compare efficacy of different dosages.
Study: NCT00873704

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: supplemental postoperative oxygen
Study: NCT02001506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FEC3-D3
Description: Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks
Study: NCT03099798

Intervention type: OTHER
Intervention: Questionnaires
Description: All patients will complete a number of questionnaires at different time points.~* SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ~* 1 week, 1 month, 3, 6 and 12 months after treatment

Intervention type: OTHER
Intervention: Questionnaires
Description: All patients will complete a number of questionnaires at different time points.~* SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ~* 1 week, 1 month, 3, 6 and 12 months after treatment

Intervention type: OTHER
Intervention: Questionnaires
Description: All patients will complete a number of questionnaires at different time points.~* SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ~* 1 week, 1 month, 3, 6 and 12 months after treatment

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI abdomen
Description: Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.
Study: NCT00856817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine + heme arginate
Description: L-arginine first, heme arginate second three day treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heme arginate + L-arginine
Description: Heme arginate first, L-arginine second three day treatment
Study: NCT04179604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Levosimendan SIMDAX 2.5 mg / ml concentrate for solution for infusion. The concentrate is a clear solution, yellow or orange, for dilution before administration. A 5 ml vial contains 12.5 mg of levosimendan. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
Study: NCT01236768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG200-15
Description: Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week patch free period.
Study: NCT03712072

Intervention type: DEVICE
Intervention: Magnetoencephalography (MEG)
Description: The purpose of the device is to measure magnetic fields produced by an individual's brain and provide information on the location of the source of the fields. Participants between the ages of 0-3 years of old whose head can fit in the MEG helmet will be the patient population used for the BabyMEG. The device will be used in this study to learn more about the somatosensory and motor networks of children who have cerebral palsy and compare their brain signals to healthy children.

Intervention type: DEVICE
Intervention: Magnetoencephalography (MEG)
Description: The purpose of the device is to measure magnetic fields produced by an individual's brain and provide information on the location of the source of the fields. Participants between the ages of 0-3 years of old whose head can fit in the MEG helmet will be the patient population used for the BabyMEG. The device will be used in this study to learn more about the somatosensory and motor networks of children who have cerebral palsy and compare their brain signals to healthy children.
Study: NCT01236768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levora
Description: One tablet of Levora will be taken each day for a 28 day cycle.
Study: NCT00499460

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: garlic powder tablets
Description: Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: garlic powder tablets
Description: Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet

Intervention type: DRUG
Group type: OTHER
Intervention: oxycodone
Description: Single administration of three 5-mg oxycodone tablets or a 15-mg dose

Intervention type: DRUG
Group type: OTHER
Intervention: oxycodone
Description: Single administration of three 5-mg oxycodone tablets or a 15-mg dose
Study: NCT01378845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tracleer
Description: 14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prostavasin
Description: Prostavasin 60 µg i.v, 5 days per week for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostavasin
Description: Prostavasin 60 µg i.v, 5 days per week for 2 weeks
Study: NCT03712072

Intervention type: DEVICE
Intervention: Magnetoencephalography (MEG)
Description: The purpose of the device is to measure magnetic fields produced by an individual's brain and provide information on the location of the source of the fields. Participants between the ages of 0-3 years of old whose head can fit in the MEG helmet will be the patient population used for the BabyMEG. The device will be used in this study to learn more about the somatosensory and motor networks of children who have cerebral palsy and compare their brain signals to healthy children.
Study: NCT02435394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Coach plus Asthma Module
Description: The intervention is for a remote coach to assist patients with asthma for practices which will use Asthma module for guidance for asthma care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Module- No Coach
Description: The intervention is for practices to use the Asthma module for guidance for asthma care without assistance by a remote coach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHADIS- no Asthma Module
Description: The practices will use the general CHADIS tool without access to the Asthma Module add-on to assist in asthma care.
Study: NCT06204146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: massage
Description: stressn level and preterm growth
Study: NCT04258384

Intervention type: OTHER
Intervention: survey application
Description: Data collection tools used in the study; Demographic Data Form, Mcgill and Melzack Pain Questionnaire, Short Form-36 (SF-36), Vanderbilt Multidimensional Pain Coping Inventory (VMPCI), Pain Coping Inventory (PCI), Pain Coping Scale were used.
Study: NCT00356473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Study: NCT01217359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: Patients will receive a single dose of interferon followed by serial blood draws to assess cellular responses to interferon
Study: NCT02312102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Chemotherapy
Study: NCT00764738

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT, Multifocal ERG, Microperimetry
Description: OCT performed monthly. Fluorescein Angiography performed at baseline, month 3, month 5, month 8 and month 12.~Microperimetry performed at baseline, month 3, month 5, month 8, and month 12 for monthly ranibizumab and at baseline, month 3, month 5 through month 12 for as needed ranibizumab.~Multifocal ERG done at the same monthly visits as the microperimetry.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT, Multifocal ERG, Microperimetry
Description: OCT performed monthly. Fluorescein Angiography performed at baseline, month 3, month 5, month 8 and month 12.~Microperimetry performed at baseline, month 3, month 5, month 8, and month 12 for monthly ranibizumab and at baseline, month 3, month 5 through month 12 for as needed ranibizumab.~Multifocal ERG done at the same monthly visits as the microperimetry.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Ophthalmic
Description: 0.5 mg ranibizumab vs 2.0 mg ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Ophthalmic
Description: 0.5 mg ranibizumab vs 2.0 mg ranibizumab
Study: NCT02968771

Intervention type: OTHER
Intervention: Non intervention
Study: NCT01828567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision making with a Prevention Coach
Description: A series of two phone sessions with a prevention coach. The first to engage the veteran to choose a preferred prevention program and link them to Patient Aligned Care Team (PACT), and a follow-up call one month later to assess the progress of the prevention plan.